Compare Allstate Corp (ALL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Allstate Corp trades at $258.52 (market cap $66.31B), while State Street SPDR S&P Biotech ETF trades at $159.54. The key difference: Allstate Corp pays a 1.65% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Allstate Corp nearer its low. Which is the better fit depends on your goals.
| ALL | XBI | |
|---|---|---|
Market Cap | $66.31B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $275.11 | $164.28 |
52-Week Low | $190.00 | $86.92 |
Enterprise Value | $74.96B | — |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.
Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
